EBV DNA in plasma had better sensitivity (A) and specificity (B) than PBMCs in distinguishing between patients with active, systemic EBV⁺ disease and patients that did not have prior, current, or subsequent history of EBV⁺ disease. See Figure 2B-C in the article by Kanakry et al that begins on page 2007.